Zenas BioPharma, Inc. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
Zenas BioPharma, Inc. (ZBIO) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $30.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2026-08-13
- Zenas BioPharma, Inc. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2026-06-30 was $30.00M.
- Zenas BioPharma, Inc. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2025-12-31 was $166.67M.
- Zenas BioPharma, Inc. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2025-09-30 was $5.00M.
- Zenas BioPharma, Inc. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2023-12-31 was $0.00.
- Zenas BioPharma, Inc. research and development asset acquired other than through business combination, fair value acquired for fiscal 2025 was $171.67M.
- Zenas BioPharma, Inc. research and development asset acquired other than through business combination, fair value acquired for fiscal 2023 was $10.00M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 3 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 6 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 9 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.00M 10-Q · filed 2026-08-13 | $30.00M 10-Q · filed 2026-08-13 | ||
| 2025-12-31 | $166.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $171.67M derived: sum of 2 quarters · filed 2026-03-16 | $171.67M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $5.00M 10-Q · filed 2025-11-12 | $5.00M 10-Q · filed 2025-11-12 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $10.00M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $10.00M 10-Q · filed 2024-11-12 |